Structurally Mapping the Diverse Phenotype of Adeno-Associated Virus Serotype 4
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
The adeno-associated viruses (AAVs) can package and deliver foreign DNA into cells for corrective gene delivery applications. The AAV serotypes have distinct cell binding, transduction, and antigenic characteristics that have been shown to be dictated by the capsid viral protein (VP) sequence. To understand the contribution of capsid structure to these properties, we have determined the crystal structure of AAV serotype 4 (AAV4), one of the most diverse serotypes with respect to capsid protein sequence and antigenic reactivity. Structural comparison of AAV4 to AAV2 shows conservation of the core β strands (βB to βI) and helical (αA) secondary structure elements, which also exist in all other known parvovirus structures. However, surface loop variations (I to IX), some containing compensating structural insertions and deletions in adjacent regions, result in local topological differences on the capsid surface. These include AAV4 having a deeper twofold depression, wider and rounder protrusions surrounding the threefold axes, and a different topology at the top of the fivefold channel from that of AAV2. Also, the previously observed “valleys” between the threefold protrusions, containing AAV2's heparin binding residues, are narrower in AAV4. The observed differences in loop topologies at subunit interfaces are consistent with the inability of AAV2 and AAV4 VPs to combine for mosaic capsid formation in efforts to engineer novel tropisms. Significantly, all of the surface loop variations are associated with amino acids reported to affect receptor recognition, transduction, and anticapsid antibody reactivity for AAV2. This observation suggests that these capsid regions may also play similar roles in the other AAV serotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AAV capsids have nine variable regions surrounded by conserved regions where the variable regions form loops and clusters on the exterior of the capsid.18–19”
From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These protrusions are formed from interdigitating loops from two VPs and have the most extensive VP–VP interactions [23,24].”
From Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses (2017) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“This region has the least number of VP–VP interface interactions and represents the thinnest region of the virus capsid shell [23,24].”
From Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses (2017) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This includes the recombinant AAV vector rAAV2.7m8 (Dalkara et al., 2013), which is derived from the natural serotype AAV2 and was isolated by directed evolution when screening for increased transduction of the mouse retina following intravitreal (IVT) administration.”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Govindasamy et al., 2006
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 4×
“This figure was generated using the Chimera program (54).”
MethodInfluentialThe PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320 · cited 1×
“The secondary structure elements were assigned using the DSSP program (30).”
MethodJones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 2×
“space electron density averaging, and rebuilding (6, 29).”
BackgroundMethodThe interpretation of protein structures: Estimation of static accessibility
Lee, B., & Richards, F. M. (1971) · Journal of Molecular Biology · doi:10.1016/0022-2836(71)90324-x · Cited by 5,850 · cited 1×
“This algorithm utilizes the method of buried surface calculation reported by Lee and Richards ( 42 ), assuming a probe radius of 1.4 A.”
MethodInfluentialAQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., & Thornton, J. (1996) · Journal of Biomolecular NMR · doi:10.1007/bf00228148 · Cited by 5,502 · cited 1×
“angles using the PROCHECK program (41) (Table 1).”
MethodNicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240 · cited 5×
“Panels A and B were generated using the BOBSCRIPT program (15) and rendered with the RASTER3d program (48); panels C and D were generated using the GRASP program (51).”
MethodInfluentialFree R value: a novel statistical quantity for assessing the accuracy of crystal structures
Brünger, A. T. (1992) · Nature · doi:10.1038/355472a0 · Cited by 3,873 · cited 1×
“A test data set of 5% was partitioned for monitoring of the refinement process ( 5 ).”
MethodKrissinel, E., & Henrick, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904026460 · Cited by 3,760
Research works printed but not linked: 2
- Kleywegt, G. J., and T. A. Jones. 1994. Halloween…masks and bones, p. 59-66. In S. Bailey, R. Hubbard, and D. Waller (ed.), From first map to final model. SERC Daresbury Laboratory, Chilton, United Kingdom.
- Muzyczka, N., and K. I. Berns. 2001. Parvoviridae: the viruses and their replication, p. 2327-2360. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, New York, N.Y.
Cited by
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Self-citationTerminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9
Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., & Asokan, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210922 · Cited by 282
Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Self-citationStructure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 255
Self-citationEngineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer
Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., & Asokan, A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.22 · Cited by 224
Self-citationRecombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
Venkatakrishnan, B., Yarbrough, J., Domsic, J., Bennett, A., Bothner, B., Kozyreva, O. G., Samulski, R. J., Muzyczka, N., McKenna, R., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.02524-12 · Cited by 225
Self-citationBasic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Self-citationAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Self-citationA myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
Yang, L., Jiang, J., Drouin, L. M., Agbandje-Mckenna, M., Chen, C., Qiao, C., Pu, D., Hu, X., Wang, D.-Z., Li, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813207106 · Cited by 210
Self-citationTwenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
“A conserved pocket under the 3‐fold symmetry axis shows the ordering of one or two nts for multiple AAV serotypes [59,60,63,64,68,69].”
BackgroundInfluentialSelf-citationMolecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181
DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny
Koerber, J. T., Jang, J.-H., & Schaffer, D. V. (2008) · Molecular Therapy · doi:10.1038/mt.2008.167 · Cited by 181
Directed evolution of adeno-associated virus to an infectious respiratory virus
Excoffon, K. J. D. A., Koerber, J. T., Dickey, D. D., Murtha, M., Keshavjee, S., Kaspar, B. K., Zabner, J., & Schaffer, D. V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813365106 · Cited by 181
Biology of adeno-associated viral vectors in the central nervous system
Murlidharan, G., Samulski, R. J., & Asokan, A. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00076 · Cited by 154
“In addition to these in vivo studies, biophysical analysis of the AAV4 capsid has revealed distinct structural features and low capsid homology among other natural AAV isolates (Padron et al., 2005; Govindasamy et al., 2006).”
BackgroundComparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics
Rayaprolu, V., Kruse, S., Kant, R., Venkatakrishnan, B., Movahed, N., Brooke, D., Lins, B., Bennett, A., Potter, T., McKenna, R., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01415-13 · Cited by 160
Self-citationMolecular Engineering of Viral Gene Delivery Vehicles
Schaffer, D. V., Koerber, J. T., & Lim, K.-I. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160514 · Cited by 159
Thermal Stability as a Determinant of AAV Serotype Identity
Bennett, A., Patel, S., Mietzsch, M., Jose, A., Lins-Austin, B., Yu, J. C., Bothner, B., McKenna, R., & Agbandje-McKenna, M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.003 · Cited by 159
Self-citationAdachi, K., Enoki, T., Kawano, Y., Veraz, M., & Nakai, H. (2014) · Nature Communications · doi:10.1038/ncomms4075 · Cited by 147
Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKenna, R., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje-McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143
Self-citationParvovirus glycan interactions
Huang, L.-Y., Halder, S., & Agbandje-McKenna, M. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.05.007 · Cited by 136
“The tops of the loops between these conserved regions are varied in sequence and structure (even within each genus) and defined as variable regions (VRs) I-IX or VR1-8 for dependo and autonomous parvoviruses, respectively [20,21].”
BackgroundSelf-citationTseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
“The conserved β-barrel core motif (βBIDG-βCHEF, gray), conserved αA helix, DE loop (between βD and βE), HI loop (between βH and βI), VR-I to VR-IX [defined (26)] are colored; I: purple, II: blue, III: yellow, IV: red, V: black, VI: hot pink, VII: cyan, VIII: green, and IX: brown; and labeled.”
BackgroundSelf-citationIdentification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid
Bell, C. L., Gurda, B. L., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.00448-12 · Cited by 138
Self-citationAdeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 151
Capsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127
“The adeno-associated viruses (AAVs) being developed as vectors for corrective human gene delivery have shown promise in clinical trials, but preexisting antibodies are detrimental to successful outcomes.”
BackgroundInfluentialSelf-citationAdeno-associated virus-2 and its primary cellular receptor—Cryo-EM structure of a heparin complex
O'Donnell, J., Taylor, K. A., & Chapman, M. S. (2009) · Virology · doi:10.1016/j.virol.2008.11.037 · Cited by 125
Giles, A. R., Sims, J. J., Turner, K. B., Govindasamy, L., Alvira, M. R., Lock, M., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.013 · Cited by 116
Self-citationThe Role of the Adeno-Associated Virus Capsid in Gene Transfer
Van Vliet, K. M., Blouin, V., Brument, N., Agbandje-McKenna, M., & Snyder, R. O. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-210-6_2 · Cited by 116
Self-citationAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Self-citationHeparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110
Self-citationNam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108
Self-citationLerch, T. F., Xie, Q., & Chapman, M. S. (2010) · Virology · doi:10.1016/j.virol.2010.03.027 · Cited by 106
Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features
Mietzsch, M., Jose, A., Chipman, P. R., Bhattacharya, N., Daneshparvar, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Viruses · doi:10.3390/v13010101 · Cited by 117
Self-citationWang, J., Xie, J., Lu, H., Chen, L., Hauck, B., Samulski, R. J., & Xiao, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702778104 · Cited by 100
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101
“A total of nine variable regions (VRs) were defined within the loop insertions based on the comparison of two serotypes, AAV2 and AAV4, which differ in sequence and structure (30).”
BackgroundSelf-citationMays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 99
Self-citationHuman Bocavirus Capsid Structure: Insights into the Structural Repertoire of the Parvoviridae
Gurda, B. L., Parent, K. N., Bladek, H., Sinkovits, R. S., DiMattia, M. A., Rence, C., Castro, A., McKENNA, R. V., Olson, N. H., Brown, K. E., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02719-09 · Cited by 117
Self-citationAslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
Self-citationMapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Self-citationStructural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95
Self-citationAndari, J. E., Renaud-Gabardos, E., Tulalamba, W., Weinmann, J., Mangin, L., Pham, Q. H., Hille, S. S., Bennett, A. D., Attebi, E., Bourges, E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4704 · Cited by 104
“8 of 21 variable regions (VRs), specifically VRs I to IX (34).”
BackgroundSelf-citationAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism
Powell, S. K., Khan, N., Parker, C. L., Samulski, R. J., Matsushima, G., Gray, S. J., & McCown, T. J. (2016) · Gene Therapy · doi:10.1038/gt.2016.62 · Cited by 92
Körbelin, J., Sieber, T., Michelfelder, S., Lunding, L., Spies, E., Hunger, A., Alawi, M., Rapti, K., Indenbirken, D., Müller, O. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.62 · Cited by 87
Parvovirus Family Conundrum: What Makes a Killer?
Kailasan, S., Agbandje‐McKenna, M., & Parrish, C. R. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055150 · Cited by 98
Self-citationBecker, J., Fakhiri, J., & Grimm, D. (2022) · Pathogens · doi:10.3390/pathogens11070756 · Cited by 79
“[36]) and tran‐ scriptional start sites for VP1, VP2 and VP3, as well as MAAP [37] and AAP [38].”
BackgroundStructure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5 Å Resolution
Lerch, T. F., O'Donnell, J. K., Meyer, N. L., Xie, Q., Taylor, K. A., Stagg, S. M., & Chapman, M. S. (2012) · Structure · doi:10.1016/j.str.2012.05.004 · Cited by 89
“A more broad comparison to all other AAV serotypes of known structure (AAV-1 to -6, and -8) shows that this region is not only distinct from the parental AAV-2 and -8, but is unique among analogous sites on AAV-1, 3, 4, 5, and 6 (Govindasamy et al., 2006; Lerch et al., 2009; Nam et al., 2007; Ng et al., 2010; Xie et a…”
InfluentialRossi, A., Dupaty, L., Aillot, L., Zhang, L., Gallien, C., Hallek, M., Odenthal, M., Adriouch, S., Salvetti, A., & Büning, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40071-1 · Cited by 85
Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20
McCraw, D. M., O’Donnell, J. K., Taylor, K. A., Stagg, S. M., & Chapman, M. S. (2012) · Virology · doi:10.1016/j.virol.2012.05.004 · Cited by 84
Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR
Meyer, N. L., Hu, G., Davulcu, O., Xie, Q., Noble, A. J., Yoshioka, C., Gingerich, D. S., Trzynka, A., David, L., Stagg, S. M., et al. (2019) · eLife · doi:10.7554/elife.44707 · Cited by 83
Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses
Bennett, A., Mietzsch, M., & Agbandje-McKenna, M. (2017) · Future Virology · doi:10.2217/fvl-2017-0011 · Cited by 82
Self-citationAdenovirus Virion Stability and the Viral Genome: Size Matters
Kennedy, M. A., & Parks, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.202 · Cited by 88
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Boye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Self-citationMarsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje-McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 72
Self-citationVandenberghe, L. H., Breous, E., Nam, H.-J., Gao, G., Xiao, R., Sandhu, A., Johnston, J., Debyser, Z., Agbandje-McKenna, M., & Wilson, J. M. (2009) · Gene Therapy · doi:10.1038/gt.2009.101 · Cited by 72
Self-citationPre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening
Börner, K., Kienle, E., Huang, L.-Y., Weinmann, J., Sacher, A., Bayer, P., Stüllein, C., Fakhiri, J., Zimmermann, L., Westhaus, A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.02.009 · Cited by 70
Self-citationStructure–function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6)
Xie, Q., Lerch, T. F., Meyer, N. L., & Chapman, M. S. (2011) · Virology · doi:10.1016/j.virol.2011.08.011 · Cited by 70
“…remain with AAV-2 vectors, including varying transduction efficiencies in different cell types, and inefficient in vivo transduction following prior exposure to AAV (Gao et al., 2005; Halbert et al., 1997, 1998; Louboutin et al., 2005; Su et al., 2008; Wang et al., 2005; Wu et al., 2006b).”
BackgroundTseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
Self-citationThe next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
Cellular pathways of recombinant adeno-associated virus production for gene therapy
Sha, S., Maloney, A. J., Katsikis, G., Nguyen, T. N. T., Neufeld, C., Wolfrum, J., Barone, P. W., Springs, S. L., Manalis, S. R., Sinskey, A. J., et al. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107764 · Cited by 67
Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8
Mietzsch, M., Barnes, C., Hull, J. A., Chipman, P. R., Xie, J., Bhattacharya, N., Sousa, D. R., McKENNA, R. V., Gao, G., & Agbandje‐McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01769-19 · Cited by 71
“The orientation of H632 in all three viruses is consistent with the DNA binding position observed in other AAVs (17, 18, 20, 21, 24, 56) and the dual orientation in AAVrh.39 appears to stabilize the phosphodiester bond between the dAMP and the 3= dCMP (Fig.”
BackgroundInfluentialSelf-citationLópez-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
Raupp, C., Naumer, M., Müller, O. J., Gurda, B. L., Agbandje-McKenna, M., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00209-12 · Cited by 64
Self-citationHsu, H.-L., Brown, A., Loveland, A. B., Lotun, A., Xu, M., Luo, L., Xu, G., Li, J., Ren, L., Su, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17047-1 · Cited by 63
Mietzsch, M., Smith, J. K., Yu, J. C., Banala, V., Emmanuel, S. N., Jose, A., Chipman, P. R., Bhattacharya, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.001 · Cited by 65
“VR-IX showed contacts to AVB at N718 and L720 (in AAV1, Figure S1), but neither residue is conserved among the AVB-binding AAVs.”
BackgroundInfluentialSelf-citationStructure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 64
“A NT has been observed in the same location for AAV1, AAV3b, AAV4, AAV6, AAV8, and AAVrh32.”
BackgroundMethodInfluentialSelf-citationJin, X., Liu, L., Nass, S., O’Riordan, C. R., Pastor, E., & Zhang, X. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.178 · Cited by 65
“30, 32,51–53 Although the experimental mass of AAV2 VP3 (59,974 Da) from intact protein analysis matches with the theoretical mass of VP3 without disulfide bonds, disulfide mapping by LC/MS/MS of native enzymatic digestion is needed to confirm cysteine status further in the AAV capsid proteins.”
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
“Each subunit contains 9 variable regions (VRs) on the surface of AAV virions, which decide the natural tropism and intracellular transport of AAV and are generally the domains for neutralizing antibody recognition [50,51].”
BackgroundMiller, E. B., Gurda-Whitaker, B., Govindasamy, L., McKenna, R., Zolotukhin, S., Muzyczka, N., & Agbandje-McKenna, M. (2006) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309106048184 · Cited by 58
Self-citationAdeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 59
“For example, AAV2 was used to characterize the first AAV glycan attachment factors and deduce the first high-resolution AAV structure, and AAV2 served as the basis for the first genome-wide screen to identify protein entry receptors [22,24,36,37].”
BackgroundMethodIdentification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B)
Lerch, T. F., & Chapman, M. S. (2012) · Virology · doi:10.1016/j.virol.2011.10.007 · Cited by 54
“Locally high B-factors in all AAV structures indicate that the region is among the most disordered (Govindasamy et al., 2006; Lerch, Xie, and Chapman, 2010; Nam et al., 2007; Ng et al., 2010; Xie et al., 2002).”
BackgroundPénzes, J. J., Chipman, P. R., Bhattacharya, N., Zeher, A., Huang, R. K., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.00843-21 · Cited by 57
Self-citationHarbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R. (2012) · Journal of General Virology · doi:10.1099/vir.0.035113-0 · Cited by 54
“…identical in amino acid sequence (Gao et al., 2003, 2004), with variations in capsid surface-oriented loops, resulting in alterations of antigenicity, tissue tropism and transduction efficiency (Govindasamy et al., 2006; Lerch et al., 2010; Lochrie et al., 2006; Nam et al., 2007; Ng et al., 2010).”
BackgroundSelf-citationStructure of an Enteric Pathogen, Bovine Parvovirus
Kailasan, S., Halder, S., Gurda, B. L., Bladek, H., Chipman, P. R., McKENNA, R. V., Brown, K. E., & Agbandje‐McKenna, M. (2014) · Journal of Virology · doi:10.1128/jvi.03157-14 · Cited by 57
Self-citationParvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje-McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 54
Self-citationJudd, J., Wei, F., Nguyen, P. Q., Tartaglia, L. J., Agbandje-McKenna, M., Silberg, J. J., & Suh, J. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.46 · Cited by 51
Self-citationDrouin, L. M., Lins, B., Janssen, M., Bennett, A., Chipman, P., McKenna, R., Chen, W., Muzyczka, N., Cardone, G., Baker, T. S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00575-16 · Cited by 52
Self-citationNance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 51
Surface Loop Dynamics in Adeno-Associated Virus Capsid Assembly
DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2008) · Journal of Virology · doi:10.1128/jvi.02721-07 · Cited by 49
“For instance, the AAV4 HI loop is composed of a higher number of hydrophobic residues than the loop from AAV2 based on the amino acid sequence and crystal structure (16).”
BackgroundSelf-citationVirus Isoelectric Point Estimation: Theories and Methods
Heffron, J., & Mayer, B. K. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.02319-20 · Cited by 52
“AAV4 Adeno-associated virus 4 Dependoparvovirus ssDNA 57579 2G8G (110) 3.”
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Li, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Self-citationCryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Cabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 46
“Comparative analysis of the capsid structure and sequenceof twodiverse serotypes,AAV2 and AAV4, defined variable regions (VRs) within these loops.(24) The VRs are responsible for functional variations between differentAAV serotypes.”
BackgroundSelf-citationJose, A., Mietzsch, M., Smith, J. K., Kurian, J., Chipman, P., McKenna, R., Chiorini, J., & Agbandje-McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01394-18 · Cited by 44
“The latter serotype does not possess the B1 epitope (8).”
BackgroundSelf-citationCabanes‐Creus, M., Navarro, R. G., Zhu, E., Baltazar, G., Liao, S. H. Y., Drouyer, M., Amaya, A. K., Scott, S., Nguyen, L. H., Westhaus, A., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.011 · Cited by 45
Shen, S., Troupes, A. N., Pulicherla, N., & Asokan, A. (2013) · Journal of Virology · doi:10.1128/jvi.02109-13 · Cited by 42
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Jacobs, F., Gordts, S. C., Muthuramu, I., & Geest, B. D. (2012) · Pharmaceuticals · doi:10.3390/ph5121372 · Cited by 48
The structure of AAVrh32.33, a novel gene delivery vector
Mikals, K., Nam, H.-J., Van Vliet, K., Vandenberghe, L. H., Mays, L. E., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.020 · Cited by 41
“33 NT is located in essentially the same position and involved in the same interactions as those reported for AAV4 and AAV8 (Govindasamy et al., 2006; Nam et al., 2007).”
InfluentialSelf-citationStructure-guided AAV capsid evolution strategies for enhanced CNS gene delivery
Gonzalez, T. J., Mitchell-Dick, A., Blondel, L. O., Fanous, M. M., Hull, J. A., Oh, D. K., Møller-Tank, S., Rivera, R. M. C., Piedrahita, J. A., & Asokan, A. (2023) · Nature Protocols · doi:10.1038/s41596-023-00875-y · Cited by 42
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
Artificial Intelligence‐Based Approaches for AAV Vector Engineering
Tan, F., Dong, Y., Qi, J., Yu, W., & Chai, R. (2025) · Advanced Science · doi:10.1002/advs.202411062 · Cited by 43
Smith, R. H., Hallwirth, C. V., Westerman, M., Hetherington, N. A., Tseng, Y.-S., Cecchini, S., Virag, T., Ziegler, M.-L., Rogozin, I. B., Koonin, E. V., et al. (2016) · Scientific Reports · doi:10.1038/srep28965 · Cited by 36
Self-citationChapman, M. S., Trzynka, A., & Chapman, B. K. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.01.003 · Cited by 34
“, 2006) using AAV-4 and AAV-5 templates (Govindasamy et al., 2006; Walters et al., 2004), structures that have <60% sequence identity to AAV-DJ’s parental strains.”
MethodSong, R., Pekrun, K., Khan, T. A., Zhang, F., Paşca, S. P., & Kay, M. A. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.002 · Cited by 36
Metadata
- Authors
- Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M.
- Affiliations
- Department of Biochemistry and Molecular Biology, Center for Structural Biology, The McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida 32610
- University of Florida (US)
- National Institutes of Health (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2006-12
- Volume
- 80
- Issue
- 23
- Pages
- 11556-11570
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC1642620
- OpenAlex
- W2149678280
- Cited by
- 205
- References
- 71
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 11 · 2021: 17 · 2020: 13 · 2019: 8 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 10 · 2013: 13 · 2012: 16
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL051811)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Infectious Diseases › Parvovirus B19 Infection Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- capsid protein, AAV2, heparin binding, receptor recognition, transduction, gene delivery vectors
- MeSH terms
- Dependovirus, Binding Sites, Capsid, Phenotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.